A nitroformate or a derivative of its salts that shows activity as a COMT inhibitor and activity as a DDC inhibitor, as well as pharmaceutical ingredients that contain this activity. 1. Characteristic requirement 1: a compound characterized by formula (1) or a salt acceptable to the drug, wherein R 1 and R 2 independently represent a hydrogen atom, a tar group substituted by c833218331833231, and a carbon group substituted by c833218331832626； A. alcox c83216c83318326 selective carbides or c8332183318326 selective carbamates； R3 represents hydrogen atom and halogen atom；A. halide group, cyanogen group or anthrax group； r83088 is a hydrogen atom, a halogen atom, a c8327a group, a c8331832626 substitute, a halide group, a cyanogen group, a anthrax group, an amino compound group, a c8331832626 substitute tar group and a halotar group； A. an alternative arilsulfanilo group, an alternative alcoxi c832131 ° - 832626 group, an alternative ariloxi group, an alternative altariloxi group, an alternative alternative altariloxi group, an alternative alcoxi c833218c833312626 alternative carboilo group, a c83121iqil group c83183326262 alternative replacement；A. alternative arilcanonio group, alternative heterosexual group, c83321318326836263 alternative sulfonil group, c833218331832626 alternative Aquil group, alternative arilsulfonilo group, alternative heterosexual group, A. alternative arilsulfinium group, alternative heterosexual group, c83321a alternative ammonium carbamate group, alternative aminosulfonilo group, alternative heterocyclopropylene glycol group, alternative benzofuran group, 2. Substituted trihydrofuranOne chrome ring, one optional 2-chrome ring, one optional 3-chrome ring replacement, one optional 4-chrome ring replacement, one optional cumarina ring replacement, one optional chrome ring replacement, one optional 2-cumarina ring replacement, one non optional replacement. A. an optional replacement ring or an optional replacement FTA ring； r8309a-r83044 respec
